This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE) | MicrobiomeTrials
← Back to trials NCT07132164
Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE) Recruiting OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-07-01Est. Completion: 2031-07-01
Enrollment target: 400 participantsLocations CHU Rouen, Rouen, Rouen, France Besançon-CIC, Besançon, France CHU Besançon, Besançon, France CHU de Bordeaux Pellegrin, Bordeaux, France CH Boulogne/mer, Boulogne-sur-Mer, France CHU de Brest, Brest, France CHU de Caen, Caen, France Clinique de l'Infirmerie Protestante de Lyon, Caluire-et-Cuire, France CHU de Clermont-Ferrand, Clermont-Ferrand, France CH Dax, Dax, France CHU de Dijon, Dijon, France CH La Roche s/ Yon, La Roche-sur-Yon, France APHP - Kremlin-Bicêtre, Le Kremlin-Bicêtre, France CH Le Mans, Le Mans, France CHU de Lille, Lille, France Institut catholique de Lille, Lomme, France CHU Marseille AP-HM, Marseille, France CH Le Havre, Montivilliers, France CHU de Montpellier, Montpellier, France CH Morlaix, Morlaix, France CHU de Nice, Nice, France AP-HP La Pitié-Salpétrière, Paris, France AP-HP Cochin, Paris, France AP-HP Bichat, Paris, France Hopital NOVO - Site Pontoise, Pontoise, France CHU Saint-Etienne, Saint-Priest-en-Jarez, France CHU Strasbourg, Strasbourg, France Clinique Ambroise Paré-Toulouse, Toulouse, France CHU de Toulouse, Toulouse, France CHU de Tours, Tours, France Other microbiome trials you might be interested in Polymyalgia Rheumatica (PMR)
Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease affecting the elderly. The diagnosis is based on establ…
Aix-en-Provence, France Est. completion Nov 2028
Vascular Complications
The development of immune checkpoint inhibitors (ICIs) has revolutionized the management of many oncological diseases, a…
Rouen, France Est. completion Aug 1, 2028